Intuitive Surgical, Inc. (ISRG) Spending and interest coverage
- R&D / revenue · 12 months: Value 12.82%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 7.49%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 12.82% | Research and development expense / revenue. Period ending 2026-06-30. $1.41B ÷ $11.03B × 100 ≈ 12.82% |
| Stock-based compensation / revenue · 12 months | 7.49% | Share-based compensation / revenue. Period ending 2026-06-30. $826.20M ÷ $11.03B × 100 ≈ 7.49% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.41B USD | Research and Development Expense |
| Revenue | 11.03B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 826.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 3.45B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.41B | $11.03B | $826.20M | $3.45B | (m) | 12.82% | 7.49% | (m) | (m) |
| 2026-03-31 | $1.36B | $10.58B | $812.50M | $3.22B | (m) | 12.83% | 7.68% | (m) | (m) |
| 2025-12-31 | $1.31B | $10.06B | $788.20M | $2.95B | (m) | 13.03% | 7.83% | (m) | (m) |
| 2025-09-30 | $1.25B | $9.61B | $761.90M | $2.82B | (m) | 13.04% | 7.93% | (m) | (m) |
| 2025-06-30 | $1.21B | $9.14B | $731.30M | $2.63B | (m) | 13.23% | 8.00% | (m) | (m) |
| 2025-03-31 | $1.18B | $8.71B | $708.70M | $2.46B | (m) | 13.51% | 8.13% | (m) | (m) |
| 2024-12-31 | $1.15B | $8.35B | $676.80M | $2.35B | (m) | 13.71% | 8.10% | (m) | (m) |
| 2024-09-30 | $1.11B | $7.87B | $650.20M | $2.06B | (m) | 14.12% | 8.27% | (m) | (m) |
| 2024-06-30 | $1.07B | $7.57B | $633.40M | $1.95B | (m) | 14.18% | 8.36% | (m) | (m) |
| 2024-03-31 | $1.04B | $7.32B | $606.30M | $1.85B | (m) | 14.19% | 8.28% | (m) | (m) |
| 2023-12-31 | $998.80M | $7.12B | $592.80M | $1.77B | (m) | 14.02% | 8.32% | (m) | (m) |
| 2023-09-30 | $982.80M | $6.85B | $570.00M | $1.69B | (m) | 14.35% | 8.32% | (m) | (m) |
| 2023-06-30 | $950.50M | $6.66B | $552.00M | $1.62B | (m) | 14.26% | 8.28% | (m) | (m) |
| 2023-03-31 | $913.40M | $6.43B | $532.20M | $1.56B | (m) | 14.20% | 8.28% | (m) | (m) |
| 2022-12-31 | $879.00M | $6.22B | $513.20M | $1.58B | (m) | 14.13% | 8.25% | (m) | (m) |
| 2022-09-30 | $818.30M | $6.12B | $503.40M | $1.66B | (m) | 13.38% | 8.23% | (m) | (m) |
| 2022-06-30 | $766.70M | $5.96B | $485.40M | $1.70B | (m) | 12.86% | 8.14% | (m) | (m) |
| 2022-03-31 | $721.70M | $5.91B | $466.80M | $1.81B | (m) | 12.22% | 7.90% | (m) | (m) |
| 2021-12-31 | $671.00M | $5.71B | $449.20M | $1.82B | (m) | 11.75% | 7.87% | (m) | (m) |
| 2021-09-30 | $637.40M | $5.49B | $434.50M | $1.79B | (m) | 11.61% | 7.92% | (m) | (m) |
| 2021-06-30 | $626.90M | $5.16B | $420.20M | $1.61B | (m) | 12.14% | 8.14% | (m) | (m) |
| 2021-03-31 | $607.80M | $4.55B | $408.00M | $1.18B | (m) | 13.36% | 8.97% | (m) | (m) |
| 2020-12-31 | $595.10M | $4.36B | $395.40M | $1.05B | (m) | 13.65% | 9.07% | (m) | (m) |
| 2020-09-30 | $601.90M | $4.31B | $381.50M | $1.03B | (m) | 13.97% | 8.86% | (m) | (m) |
| 2020-06-30 | $582.80M | $4.36B | $364.60M | $1.13B | (m) | 13.37% | 8.37% | (m) | (m) |
| 2020-03-31 | $560.40M | $4.60B | $350.30M | $1.41B | (m) | 12.17% | 7.61% | (m) | (m) |
| 2019-12-31 | $557.30M | $4.48B | $335.80M | $1.37B | (m) | 12.44% | 7.50% | (m) | (m) |
| 2019-09-30 | $520.60M | $4.25B | $317.00M | $1.31B | (m) | 12.26% | 7.46% | (m) | (m) |
| 2019-06-30 | $492.30M | $4.04B | $298.10M | $1.26B | (m) | 12.19% | 7.38% | (m) | (m) |
| 2019-03-31 | $466.60M | $3.85B | $279.80M | $1.17B | (m) | 12.12% | 7.27% | (m) | (m) |
| 2018-12-31 | $418.10M | $3.72B | $261.20M | $1.20B | (m) | 11.23% | 7.01% | (m) | (m) |
| 2018-09-30 | $385.30M | $3.56B | $246.40M | $1.19B | (m) | 10.82% | 6.92% | (m) | (m) |
| 2018-06-30 | $361.10M | $3.45B | $232.10M | $1.16B | (m) | 10.47% | 6.73% | (m) | (m) |
| 2018-03-31 | $350.60M | $3.30B | $219.20M | $1.14B | (m) | 10.63% | 6.65% | (m) | (m) |
| 2017-12-31 | $328.60M | $3.13B | $209.10M | $1.05B | (m) | 10.50% | 6.68% | (m) | (m) |
| 2017-09-30 | $310.60M | $2.99B | $199.00M | $992.00M | (m) | 10.38% | 6.65% | (m) | (m) |
| 2017-06-30 | $289.80M | $2.87B | $190.10M | $969.80M | (m) | 10.10% | 6.62% | (m) | (m) |
| 2017-03-31 | $259.90M | $2.78B | $182.30M | $957.70M | (m) | 9.34% | 6.55% | (m) | (m) |
| 2016-12-31 | $239.60M | $2.70B | $177.60M | $945.20M | (m) | 8.86% | 6.57% | (m) | (m) |
| 2016-09-30 | $223.10M | $2.62B | $173.40M | $926.70M | (m) | 8.50% | 6.61% | (m) | (m) |
| 2016-06-30 | $211.50M | $2.53B | $170.80M | $860.20M | (m) | 8.36% | 6.75% | (m) | (m) |
| 2016-03-31 | $206.20M | $2.45B | $169.50M | $788.60M | (m) | 8.43% | 6.93% | (m) | (m) |
| 2015-12-31 | $197.40M | $2.38B | $167.90M | $740.00M | (m) | 8.28% | 7.04% | (m) | (m) |
| 2015-09-30 | $192.10M | $2.31B | $167.70M | $680.20M | (m) | 8.31% | 7.25% | (m) | (m) |
| 2015-06-30 | $188.60M | $2.27B | $168.60M | $649.40M | (m) | 8.30% | 7.42% | (m) | (m) |
| 2015-03-31 | $179.40M | $2.20B | $169.20M | $618.60M | (m) | 8.16% | 7.69% | (m) | (m) |
| 2014-12-31 | $178.00M | $2.13B | $168.90M | $544.80M | (m) | 8.35% | 7.92% | (m) | (m) |
| 2014-09-30 | $172.40M | $2.10B | $169.40M | $567.30M | (m) | 8.20% | 8.05% | (m) | (m) |
| 2014-06-30 | $168.10M | $2.05B | $174.70M | $582.40M | (m) | 8.19% | 8.51% | (m) | (m) |
| 2014-03-31 | $169.10M | $2.12B | $171.50M | $657.90M | (m) | 7.98% | 8.10% | (m) | (m) |
| 2013-12-31 | $167.70M | $2.27B | $168.90M | $852.50M | (m) | 7.40% | 7.46% | (m) | (m) |
| 2013-09-30 | $167.70M | $2.30B | $165.60M | $892.00M | (m) | 7.30% | 7.21% | (m) | (m) |
| 2013-06-30 | $174.20M | $2.34B | $162.50M | $929.20M | (m) | 7.45% | 6.95% | (m) | (m) |
| 2013-03-31 | $173.20M | $2.29B | $157.10M | $936.00M | (m) | 7.55% | 6.85% | (m) | (m) |
| 2012-12-31 | $170.00M | $2.18B | $153.30M | $878.10M | (m) | 7.80% | 7.04% | (m) | (m) |
| 2012-09-30 | $169.70M | $2.07B | $149.60M | $829.50M | (m) | 8.21% | 7.24% | (m) | (m) |
| 2012-06-30 | $155.40M | $1.98B | $137.20M | $797.00M | (m) | 7.87% | 6.95% | (m) | (m) |
| 2012-03-31 | $147.20M | $1.86B | $138.70M | $739.80M | (m) | 7.90% | 7.44% | (m) | (m) |
| 2011-12-31 | $140.20M | $1.76B | $136.40M | $694.80M | (m) | 7.98% | 7.76% | (m) | (m) |
| 2011-09-30 | $131.40M | $1.65B | $131.90M | $649.00M | (m) | 7.96% | 7.99% | (m) | (m) |
| 2011-06-30 | $122.90M | $1.55B | $127.40M | $602.20M | (m) | 7.94% | 8.23% | (m) | (m) |
| 2011-03-31 | $119.40M | $1.47B | $122.90M | $573.80M | (m) | 8.11% | 8.35% | (m) | (m) |
| 2010-12-31 | $116.00M | $1.41B | $117.60M | $555.20M | (m) | 8.21% | 8.32% | (m) | (m) |
| 2010-09-30 | $109.20M | $1.35B | $112.58M | $529.94M | (m) | 8.11% | 8.36% | (m) | (m) |
| 2010-06-30 | $106.90M | $1.28B | $106.68M | $502.34M | (m) | 8.34% | 8.32% | (m) | (m) |
| 2010-03-31 | $101.80M | $1.19B | $101.08M | $462.14M | (m) | 8.54% | 8.48% | (m) | (m) |
| 2009-12-31 | $95.10M | $1.05B | $96.98M | $377.44M | (m) | 9.04% | 9.22% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $79.37M | $874.92M | $76.65M | $310.83M | (m) | 9.07% | 8.76% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $48.86M | $600.83M | $36.29M | $206.74M | (m) | 8.13% | 6.04% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edwards Lifesciences Corp (EW) | United States | $49.409B | 51.96 |
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |